Mechanistically, these inhibitors increased mitochondrial membrane potential (Δψm) in the RET tumor cells, subsequently facilitating tumor cell uptake and retention of Δψm-sensitive triphenyl phosphonium (TPP)-conjugated carboxy-proxyl (MitoCP) and ubiquinone (MitoQ). The gene discussed is RET; the disease is neoplasm.